Prediagnostic leukocyte telomere length and pancreatic cancer survival

Tsuyoshi Hamada, Chen Yuan, Ying Bao, Mingfeng Zhang, Natalia Khalaf, Ana Babic, Vicente Morales-Oyarvide, Barbara B. Cochrane, J. Michael Gaziano, Edward L. Giovannucci, Peter Kraft, Jo Ann E. Manson, Kimmie Ng, Jonathan A. Nowak, Thomas E. Rohan, Howard D. Sesso, Meir J. Stampfer, Laufey T. Amundadottir, Charles S. Fuchs, Immaculata de VivoShuji Ogino, Brian M. Wolpin

Research output: Contribution to journalArticle

Abstract

Background: Leukocyte telomere length has been associated with risk of subsequent pancreatic cancer. Few prospective studies have evaluated the association of prediagnostic leukocyte telomere length with pancreatic cancer survival. Methods: We prospectively examined the association of prediagnostic leukocyte telomere length with overall survival (OS) time among 423 participants diagnosed with pancreatic adenocarcinoma between 1984 and 2008 within the Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, and Women's Health Initiative. We measured prediagnostic leukocyte telomere length in banked blood samples using quantitative PCR. Cox proportional hazards models were used to estimate HRs for OS with adjustment for potential confounders. We also evaluated 10 SNPs at the telomerase reverse transcriptase locus. Results: Shorter prediagnostic leukocyte telomere length was associated with reduced OS among patients with pancreatic cancer (Ptrend ¼ 0.04). The multivariable-adjusted HR for OS comparing the lowest with highest quintiles of leukocyte telomere length was 1.39 (95% confidence interval, 1.01–1.93), corresponding to a 3-month difference in median OS time. In an analysis excluding cases with blood collected within 2 years of cancer diagnosis, the association was moderately stronger (HR, 1.55; 95% confidence interval, 1.09–2.21; comparing the lowest with highest quintiles; Ptrend ¼ 0.01). No prognostic association or effect modification for the prognostic association of prediagnostic leukocyte telomere length was noted in relation to the studied SNPs. Conclusions: Prediagnostic leukocyte telomere length was associated with pancreatic cancer survival. Impact: Prediagnostic leukocyte telomere length can be a prognostic biomarker in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1868-1875
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume28
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Telomere
Pancreatic Neoplasms
Leukocytes
Survival
Single Nucleotide Polymorphism
Health
Confidence Intervals
Telomerase
Women's Health
Proportional Hazards Models
Adenocarcinoma
Biomarkers
Nurses
Prospective Studies
Physicians
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Hamada, T., Yuan, C., Bao, Y., Zhang, M., Khalaf, N., Babic, A., ... Wolpin, B. M. (2019). Prediagnostic leukocyte telomere length and pancreatic cancer survival. Cancer Epidemiology Biomarkers and Prevention, 28(11), 1868-1875. https://doi.org/10.1158/1055-9965.EPI-19-0577

Prediagnostic leukocyte telomere length and pancreatic cancer survival. / Hamada, Tsuyoshi; Yuan, Chen; Bao, Ying; Zhang, Mingfeng; Khalaf, Natalia; Babic, Ana; Morales-Oyarvide, Vicente; Cochrane, Barbara B.; Michael Gaziano, J.; Giovannucci, Edward L.; Kraft, Peter; Manson, Jo Ann E.; Ng, Kimmie; Nowak, Jonathan A.; Rohan, Thomas E.; Sesso, Howard D.; Stampfer, Meir J.; Amundadottir, Laufey T.; Fuchs, Charles S.; de Vivo, Immaculata; Ogino, Shuji; Wolpin, Brian M.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 28, No. 11, 01.01.2019, p. 1868-1875.

Research output: Contribution to journalArticle

Hamada, T, Yuan, C, Bao, Y, Zhang, M, Khalaf, N, Babic, A, Morales-Oyarvide, V, Cochrane, BB, Michael Gaziano, J, Giovannucci, EL, Kraft, P, Manson, JAE, Ng, K, Nowak, JA, Rohan, TE, Sesso, HD, Stampfer, MJ, Amundadottir, LT, Fuchs, CS, de Vivo, I, Ogino, S & Wolpin, BM 2019, 'Prediagnostic leukocyte telomere length and pancreatic cancer survival', Cancer Epidemiology Biomarkers and Prevention, vol. 28, no. 11, pp. 1868-1875. https://doi.org/10.1158/1055-9965.EPI-19-0577
Hamada, Tsuyoshi ; Yuan, Chen ; Bao, Ying ; Zhang, Mingfeng ; Khalaf, Natalia ; Babic, Ana ; Morales-Oyarvide, Vicente ; Cochrane, Barbara B. ; Michael Gaziano, J. ; Giovannucci, Edward L. ; Kraft, Peter ; Manson, Jo Ann E. ; Ng, Kimmie ; Nowak, Jonathan A. ; Rohan, Thomas E. ; Sesso, Howard D. ; Stampfer, Meir J. ; Amundadottir, Laufey T. ; Fuchs, Charles S. ; de Vivo, Immaculata ; Ogino, Shuji ; Wolpin, Brian M. / Prediagnostic leukocyte telomere length and pancreatic cancer survival. In: Cancer Epidemiology Biomarkers and Prevention. 2019 ; Vol. 28, No. 11. pp. 1868-1875.
@article{8824f746641e4d57a27f24130bded095,
title = "Prediagnostic leukocyte telomere length and pancreatic cancer survival",
abstract = "Background: Leukocyte telomere length has been associated with risk of subsequent pancreatic cancer. Few prospective studies have evaluated the association of prediagnostic leukocyte telomere length with pancreatic cancer survival. Methods: We prospectively examined the association of prediagnostic leukocyte telomere length with overall survival (OS) time among 423 participants diagnosed with pancreatic adenocarcinoma between 1984 and 2008 within the Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, and Women's Health Initiative. We measured prediagnostic leukocyte telomere length in banked blood samples using quantitative PCR. Cox proportional hazards models were used to estimate HRs for OS with adjustment for potential confounders. We also evaluated 10 SNPs at the telomerase reverse transcriptase locus. Results: Shorter prediagnostic leukocyte telomere length was associated with reduced OS among patients with pancreatic cancer (Ptrend ¼ 0.04). The multivariable-adjusted HR for OS comparing the lowest with highest quintiles of leukocyte telomere length was 1.39 (95{\%} confidence interval, 1.01–1.93), corresponding to a 3-month difference in median OS time. In an analysis excluding cases with blood collected within 2 years of cancer diagnosis, the association was moderately stronger (HR, 1.55; 95{\%} confidence interval, 1.09–2.21; comparing the lowest with highest quintiles; Ptrend ¼ 0.01). No prognostic association or effect modification for the prognostic association of prediagnostic leukocyte telomere length was noted in relation to the studied SNPs. Conclusions: Prediagnostic leukocyte telomere length was associated with pancreatic cancer survival. Impact: Prediagnostic leukocyte telomere length can be a prognostic biomarker in pancreatic cancer.",
author = "Tsuyoshi Hamada and Chen Yuan and Ying Bao and Mingfeng Zhang and Natalia Khalaf and Ana Babic and Vicente Morales-Oyarvide and Cochrane, {Barbara B.} and {Michael Gaziano}, J. and Giovannucci, {Edward L.} and Peter Kraft and Manson, {Jo Ann E.} and Kimmie Ng and Nowak, {Jonathan A.} and Rohan, {Thomas E.} and Sesso, {Howard D.} and Stampfer, {Meir J.} and Amundadottir, {Laufey T.} and Fuchs, {Charles S.} and {de Vivo}, Immaculata and Shuji Ogino and Wolpin, {Brian M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1055-9965.EPI-19-0577",
language = "English (US)",
volume = "28",
pages = "1868--1875",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Prediagnostic leukocyte telomere length and pancreatic cancer survival

AU - Hamada, Tsuyoshi

AU - Yuan, Chen

AU - Bao, Ying

AU - Zhang, Mingfeng

AU - Khalaf, Natalia

AU - Babic, Ana

AU - Morales-Oyarvide, Vicente

AU - Cochrane, Barbara B.

AU - Michael Gaziano, J.

AU - Giovannucci, Edward L.

AU - Kraft, Peter

AU - Manson, Jo Ann E.

AU - Ng, Kimmie

AU - Nowak, Jonathan A.

AU - Rohan, Thomas E.

AU - Sesso, Howard D.

AU - Stampfer, Meir J.

AU - Amundadottir, Laufey T.

AU - Fuchs, Charles S.

AU - de Vivo, Immaculata

AU - Ogino, Shuji

AU - Wolpin, Brian M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Leukocyte telomere length has been associated with risk of subsequent pancreatic cancer. Few prospective studies have evaluated the association of prediagnostic leukocyte telomere length with pancreatic cancer survival. Methods: We prospectively examined the association of prediagnostic leukocyte telomere length with overall survival (OS) time among 423 participants diagnosed with pancreatic adenocarcinoma between 1984 and 2008 within the Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, and Women's Health Initiative. We measured prediagnostic leukocyte telomere length in banked blood samples using quantitative PCR. Cox proportional hazards models were used to estimate HRs for OS with adjustment for potential confounders. We also evaluated 10 SNPs at the telomerase reverse transcriptase locus. Results: Shorter prediagnostic leukocyte telomere length was associated with reduced OS among patients with pancreatic cancer (Ptrend ¼ 0.04). The multivariable-adjusted HR for OS comparing the lowest with highest quintiles of leukocyte telomere length was 1.39 (95% confidence interval, 1.01–1.93), corresponding to a 3-month difference in median OS time. In an analysis excluding cases with blood collected within 2 years of cancer diagnosis, the association was moderately stronger (HR, 1.55; 95% confidence interval, 1.09–2.21; comparing the lowest with highest quintiles; Ptrend ¼ 0.01). No prognostic association or effect modification for the prognostic association of prediagnostic leukocyte telomere length was noted in relation to the studied SNPs. Conclusions: Prediagnostic leukocyte telomere length was associated with pancreatic cancer survival. Impact: Prediagnostic leukocyte telomere length can be a prognostic biomarker in pancreatic cancer.

AB - Background: Leukocyte telomere length has been associated with risk of subsequent pancreatic cancer. Few prospective studies have evaluated the association of prediagnostic leukocyte telomere length with pancreatic cancer survival. Methods: We prospectively examined the association of prediagnostic leukocyte telomere length with overall survival (OS) time among 423 participants diagnosed with pancreatic adenocarcinoma between 1984 and 2008 within the Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, and Women's Health Initiative. We measured prediagnostic leukocyte telomere length in banked blood samples using quantitative PCR. Cox proportional hazards models were used to estimate HRs for OS with adjustment for potential confounders. We also evaluated 10 SNPs at the telomerase reverse transcriptase locus. Results: Shorter prediagnostic leukocyte telomere length was associated with reduced OS among patients with pancreatic cancer (Ptrend ¼ 0.04). The multivariable-adjusted HR for OS comparing the lowest with highest quintiles of leukocyte telomere length was 1.39 (95% confidence interval, 1.01–1.93), corresponding to a 3-month difference in median OS time. In an analysis excluding cases with blood collected within 2 years of cancer diagnosis, the association was moderately stronger (HR, 1.55; 95% confidence interval, 1.09–2.21; comparing the lowest with highest quintiles; Ptrend ¼ 0.01). No prognostic association or effect modification for the prognostic association of prediagnostic leukocyte telomere length was noted in relation to the studied SNPs. Conclusions: Prediagnostic leukocyte telomere length was associated with pancreatic cancer survival. Impact: Prediagnostic leukocyte telomere length can be a prognostic biomarker in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85074445748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074445748&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-19-0577

DO - 10.1158/1055-9965.EPI-19-0577

M3 - Article

C2 - 31427306

AN - SCOPUS:85074445748

VL - 28

SP - 1868

EP - 1875

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -